MedWatch

Coloplast raises EBIT margin guidance

Optimizations and lower expenses due to covid-19 mean that medtech firm Coloplast has upgraded its expected EBIT margin guidance. Simultaneously, the ostomy business is advancing compared with the same period last year.

Photo: Coloplast / PR

On Thursday, Danish medtech firm Coloplast raised its margin guidance for earnings before interest and taxation (EBIT) for the whole year. The firm reports that the upgrade is due to optimizations and lower costs brought about by the covid-19 pandemic.

Now, the medtech firm expects to have an EBIT margin of 32-33 percent, whereas the previous estimate was 31-32 percent. In terms of organic growth in revenue, the firm predicts a 7-8 percent increase after currency adjustments.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs